Binding of fibrinogen to platelet integrin α IIb β 3 mediates platelet aggregation, and thus inhibition of α IIb β 3 represents a powerful therapeutic strategy in cardiovascular medicine. However, the currently used inhibitors of α IIb β 3 demonstrate several adverse effects like thrombocytopenia and bleeding, which are associated with their property to bind to non-activated α IIb β 3 . To circumvent these problems, we designed blocking single-chain antibody-fragments (scFv) that bind to α IIb β 3 exclusively in its activated conformation. Two naïve phage libraries were created: a natural phage library, based on human lymphocyte cDNA, and a synthetic library, with randomized V H CDR3. We performed serial rounds of subtractive panning with depletion on non-activated and selection on activated α IIb β 3 , which were provided on resting and ADP-stimulated platelets and CHO cells, expressing wild-type or mutated and thereby activated α IIb β 3 . In contrast to isolated, immobilized targets, as generally used for phage display, this unique cell-based approach for panning allowed the preservation of functional integrin conformation. Thereby, we obtained several scFv-clones that demonstrated exclusive binding to activated platelets and complete inhibition of fibrinogen binding and platelet aggregation. Interestingly, all activationspecific clones contained an RXD pattern in the HCDR3. Binding studies on transiently expressed point mutants and mouse-human domain-switch mutants of α IIb β 3 indicate a binding site similar to fibrinogen. In conclusion, we generated human activation-specific scFvs against α IIb β 3 , which bind selectively to activated α IIb β 3 and thereby potently inhibit fibrinogen binding to α IIb β 3 and platelet aggregation.
fibrinogen are present in the blood circulation in abundance (1, 2) . However, the fateful binding of these two molecules, leading to platelet aggregation and thrombus formation, is possible only when the receptor adopts its activated conformation, which can be induced by inside-out signaling. Thus, the specificity of the soluble fibrinogen molecule for the activated conformation of the α IIb β 3 receptor is a crucial attribute in the regulation of hemostasis. In contrast, immobilized fibrinogen, which is for example exposed on injured vessel walls, demonstrates a distinct conformation and allows the binding of non-activated as well as activated α IIb β 3 receptors (3). The detailed structural alterations that comprise the conformational changes of integrins during their activation have been studied intensively but are still not completely unraveled (4, 5) . Likewise, the molecular and structural requirements that are crucial for activation specificity of ligands are not yet fully understood.
Corresponding to its central role in thrombus formation, α IIb β 3 is one of the most attractive targets for anti-platelet therapy. The α IIb β 3 -blocking chimeric mouse-human Fab-fragment abciximab, the cyclic peptide eptifibatide, and the synthetic peptido-mimetic tirofiban have been successfully used in patients with acute myocardial infarction, unstable angina, or angioplasty (6, 7) . However, this current type of α IIb β 3 blockade is accompanied by several adverse effects: Bleeding complications are frequent with a 1% prevalence of severe thrombocytopenia (8, 9) . Furthermore, α IIb β 3 inhibitors have been described to induce paradoxical platelet activation (10) (11) (12) . The use of oral α IIb β 3 inhibitors has even been associated with a significant increase in mortality in large clinical studies, partially due to prothrombotic events (13) (14) (15) . All of these problems are associated with the property of the inhibitors to bind to the receptor, irrespective of its activation state, and to act partially as ligand-mimetics (10, 11) . Hence, a α IIb β 3 inhibitor, which binds exclusively to activated platelets, promises to be more advantageous for clinical use. However, Pac-1, the only activation-specific blocking antibody presently available, is a large multivalent IgM molecule and as such is not suitable for clinical use; its Fab fragments demonstrate a rather low affinity (16) . Thus, the goal of this study was to design high-affinity α IIb β 3 inhibitors that are specially modeled to bind to the activated and not to the resting form of the integrin receptor. To accomplish this, we used the versatile means of the single-chain (scFv) antibody phage display technology: Single-chain antibodies contain the variable regions of the heavy and the light chain, connected by a short linker peptide (17) (18) (19) (20) . Thereby, they represent the minimal functional structure of an antibody molecule and are ideally suitable for phage display. If desirable, scFvs can be of complete human origin, avoiding major immunological incompatibilities.
Since to our knowledge no selection strategy for single-chain antibodies that have to specifically recognize function and conformation-dependent epitopes on complex cell surface proteins has been described, we had to develop a new selection strategy. In contrast to the standard presentation of the target as an immobilized protein, we chose the presentation of the target as an intact, functionally, and conformationally active cell surface protein. Moreover, we used for the first time naïve phage libraries for the selection of anti-α IIb β 3 single-chain antibodies.
In this paper, we present a unique cell-based protocol of differential subtractive phage display suitable to obtain single-chain antibodies directed exclusively against the active conformation of α IIb β 3 . Moreover, we provide evidence that the obtained single-chain antibodies can inhibit ADP-induced fibrinogen binding to α IIb β 3 and to block platelet aggregation. Finally, we provide detailed data, which allow to map the binding site of the obtained single-chain antibodies within α IIb β 3 .
MATERIALS AND METHODS

Construction of the natural library
A large phage display library of human scFv antibody fragments (natural library) was prepared in principle as described previously (21, 22) , using a modified set of PCR-primers and avoiding wobble positions. We isolated mRNA from peripheral blood lymphocytes (PBL) of five healthy human donors and from spleen biopsy material of six additional donors and transcribed them into cDNA. The cDNA of each donor was used separately as a template in a two-step PCR amplification process. Variable domains of V H and V L genes were first amplified using primers specific for µ, λ and κ chains. The obtained fragments were reamplified with a homologous set of primers, which introduced restriction sites appropriate for cloning purposes (NcoI and HindIII for V H and MluI and NotI for V L ) (22) . As a vector for phage surface display, phagemid pEXHAM1 was used, which was derived from pSEX81 (23) by inserting a DNA sequenceencoding a tag that consisted of six histidine residues (His(6)-tag), an amber stop codon, and a cmyc epitope between scFv and the pIII gene. V H domains were cloned in pEXHAM1, which resulted in five PBL and six spleen-derived sublibraries that contained between 1.5 × 10 6 and 7.7 × 10 7 single clones of transformed E. coli XL1-blue bacteria each. Variable domains of lambda and kappa light chains originating from each donor were cloned separately into the corresponding V H sublibrary by a series of transformations that resulted in a total complexity of 1.8 × 10 9 single clones (7.9×10 8 clones PBL-derived and 9.6×10 8 spleen-derived).
Construction of the synthetic V H library
A synthetic scFv library with mutated V H chains was generated by using two scFvs isolated from a large human scFv library as master frameworks. One scFv (E4) is directed against estradiol, the other one (C9) against hepatitis B virus surface antigen (21) . The V H CDR3's of both master frameworks were replaced by synthetic DNA oligonucleotides that contained the sequence TGT GCG ARA (NNK) 4-7 TTT GAS TAC encoding CDR3 loops of 7 to 10 amino acids of the partly randomized amino acid sequence C A K/R X 4-7 F E/D Y. Oligos were cloned separately in pEXHAM1 derivatives containing E4 or C9 scFv-genes generating libraries of 6.1 × 10 8 single clones (3.2×10 8 E4 and 2.9×10 8 C9 derivatives) by transforming E.coli XL1-blue. The size of the individual libraries exceeds either the possible number of permutations (in the case of four, five, and six randomized residues) or 10 8 individual members (seven randomized residues). Alternatively, the V H CDR3's of C9 and E4 were replaced by the corresponding region amplified by PCR from PBL and spleen-derived cDNA of human donors used for the construction of the natural library. Four separate libraries were generated in this way containing together 1 × 10 8 additional E.coli XL1-blue clones.
Construction of the synthetic V L library and shuffling of V L domains in selected scFvs
For shuffling purposes, a synthetic scFv library with mutated V L chains was generated from the E4 and the C9 master framework by replacing the V L CDR3's by synthetic DNA oligonucleotides containing the sequence CAA GTG TGG (NNK) [4] [5] [6] GTG GTA (encoding Q V W X 4-7 V V in case of C9) or AAC TCC CGG (NNK) [4] [5] [6] GTG CTA (encoding N S R X 4-6 V L in case of E4), which introduces four to six random amino acid residues at the V L JL joining position. Oligonucleotides were cloned separately in pEXHAM1 derivatives containing E4 or C9 scFv genes, which generated libraries of 6.0 × 10 7 single clones (3.5×10 7 E4 and 2.5×10 7 C9 derivatives) by transformation of E.coli XL1-blue. The size of the individual libraries exceeds either the possible number of permutations in case of four and five randomized residues or reaches 10 7 individual members (six randomized residues). As described for V H libraries, the V L CDR3's of E4 and C9 (λ chains) were also replaced by the corresponding regions amplified by PCR from PBL and the spleen-derived cDNA of human donors. Four separate libraries were generated containing altogether 2.3 × 10 7 additional E.coli XL1-blue clones.
For chain shuffling, complete light chains of selected scFv clones isolated by screening on α IIb β 3 (SA2, 3, 8, 10 and 11, all E4 derivatives) were replaced by randomized light chains from the synthetic E4 derived V L library by using MluI/NotI-DNA fragments. For each clone, a separate sublibrary of more than 2×10 7 single clones was generated by repeated transformations of E.coli XL1-blue.
Generation and culture of α IIb β 3 -expressing CHO cell lines
Chinese hamster ovary (CHO) cells were obtained from the American Type Culture Collection (Rockville, MD) and were maintained in Dulbecco's modified minimal essential medium (DMEM), 10% fetal calf serum (FCS), 2 mM L-glutamine, and 1% MEM non-essential amino acids (Gibco, Eggenstein, Germany). The cDNA of α IIb and β 3 were cloned into the expression vector pCDM8. A chimera α IIb α L , which lacks the VGFFK sequence and has the cytoplasmic domain of α L attached as a tag to the transmembrane domains of α IIb , was created as described previously (24) . The deletion of the VGFFK sequence results in a fixed high-affinity state, whereas the exchange of the cytoplasmic domains itself, without VGFFK deletion, did not result in an affinity change of the receptor. CHO cells were transfected by electroporation with 10 µg of α IIb , α IIb α L , and β 3 in pCDM8 and 0.5 µg pCDM8 with a neomycin resistance gene insert added to 1.5 × 10 7 CHO cells in 800 µl regular cell culture medium. After two days, cells were selected for resistance to 700 µg/ml G418 (Genetecin; Gibco). Cell lines with comparable expression levels were selected by flow cytometry using commercially available mAbs against α IIb , β 3 , and the complex α IIb β 3 .
Panning
All procedures were performed separately with the synthetic library and the natural library, respectively. The first round of panning was performed on human platelets: Initially, phages 1000-fold over the complexity of the starting libraries were added to 10 6 platelets in Tyrode's buffer (150 mM NaCl; 2.5 mM KCl; 12 mM NaHCO 3 ; 2 mM MgCl 2 ; 2 mM CaCl 2 ; 1 mg/ml bovine serum albumin (BSA); and 1 mg/ml dextrose, pH 7.4) and incubated 2 h at room temperature. Then, the platelets were sedimented by centrifugation (10 min, 1000 g), and the supernatant was transferred to a fresh Falcon tube and incubated with fresh, washed platelets, which were stimulated with 20 µM ADP. After 1 h incubation at room temperature the platelets were washed twice in modified HEPES-modified Tyrode's buffer (10 mM HEPES; 12 mM NaHCO 3 ; 138 mM NaCl; 2.9 mM KCl; 2 mM MgCl 2 ; 2 mM CaCl 2 ; 1 g/l glucose; and 1 g/l BSA, pH=6.5). Bound phages were then eluted by two distinct strategies: (1) Standard elution by incubation with 0.1 M gylcine (pH=2.2) for 15 min, followed by neutralization with 1/10 volume of 2M Tris HCl (pH=8). (2) Competitive elution by incubation with highly saturating concentrations (2 mg/ml) of abciximab (Eli Lilly, Indianapolis, IA) for 30 min at room temperature. The rescued phages were used for infection of log-phase XL-1-blue bacteria, which were plated on 14 cm agar plates containing 50 mM glucose, 100 µg/ml ampicillin, and 20 µg/ml tetracycline. Resuspension, infection with M13 KO7 helper-phages, and polyethylene glycol (PEG)-precipitation were performed as described above. Then, two rounds on α IIb β 3 -expressing CHO cells were performed according to the protocol described above with the following modifications: For the depletion step, the phages from the previous round (1000-fold over the output number) were incubated with 2 × 10 7 wild-type α IIb β 3 -expressing CHO cells in modified Tyrode's buffer and for selection VGFFK-deleted, "activated" α IIb β 3 -expressing CHO cells were used and further treated as described above.
The natural and synthetic libraries demonstrated a very similar course of panning: In the first round of panning, we started with 1.8x10 12 respectively 7.5x10 11 phages. With both libraries, 2.5x10 5 phages were selected. In the second round, after change of the cell background by using α IIb β 3 -expressing CHO cells, a marked reduction to as few as 3000 selected phages was achieved. Finally, in the last round with identical conditions, an extensive increase of eluted phages (output-clones) with up to 2.5x10 5 was obtained. These numbers clearly indicate an enrichment of specific clones.
Panning of the sublibraries
Five rounds of panning with the synthetic sublibraries were performed on CHO cells expressing activated α IIb β 3 as described above. But in contrast to the previous protocol, only 10 5 CHO cells were used for selection. In the first five rounds, phages were eluted solely by pH reduction and in the final round a gradient elution with increasing concentrations (0.1-1000 µg/ml) of eptifibatide (Cor Therapeutics, San Francisco, California) was performed. Using this approach, we detached large numbers of phages with medium concentrations of eptifibatide (1 and 10 µg/ml) and decreasing numbers with very high concentrations (100 and 1000 µg/ml). Phages that were not detached by lower concentrations but then eluted by 1000 µg/ml were further processed.
High-level expression and purification
The clones MA2, SA2, and SCE5 were expressed and prepared as described (25) . Briefly, the phagemid DNA was cloned, in the expression vector pHOG-21 using the restriction enzymes NcoI and NotI and transformed into TG-1 E. coli. These bacteria were grown at 37°C to an optical density of 0.8 in LB-medium containing glucose (50 mM). Then, bacteria were transferred to LB-medium containing 0.4 M sucrose and 0.25 mM Isopropyl-β-D-galactoside (IPTG) and incubated for 16 h at 200 rpm and 23°C. Finally, the bacteria were transferred to an ice-cold hyperosmotic shock solution (20% sucrose, EDTA, Tris) and incubated 1 h on ice. Then, scFv was purified from other periplasmatic proteins by FPLC using metal affinity chromatography in a first step and anion exchange chromatography in a second step. Production and purification were monitored by SDS-PAGE and Western blotting.
Flow cytometry
Blood was collected by venipuncture with a 21 gauge butterfly needle from healthy volunteers and anticoagulated with citric acid. For detection of scFv binding to activated platelets, blood was diluted 1/50 in Tyrode's buffer, if needed activated by addition of 20 µM ADP, and then incubated for 20 min with various concentrations of purified scFv or 10 µl periplasmic product. Then, the suspension was incubated a second time for 20 min at room temperature with a monoclonal, FITC-labeled anti-His(6)-tag-antibody (Dianova, Hamburg, Germany). After fixation with Cellfix (Becton Dickinson, San Diego, California) samples were measured in a FACS-Calibur flow cytometer (Becton Dickinson). For estimation of the inhibitory potency of the scFv antibodies diluted whole blood (again 1/50 in Tyrode's buffer) was stimulated with 20 µM ADP and incubated with increasing concentrations of scFv for 10 min at room temperature. Then bound fibrinogen was detected with a polyclonal FITC-labeled chicken-anti-fibrinogen antibody (WAK-Chemie, Bad Soden, Germany) in flow cytometry. Ligand-induced conformational change was monitored using the anti-ligand-induced binding site antibody LIBS-145-mAb as described previously (26) . Briefly, whole blood was diluted as described above and preincubated for 10 min at room temperature with saturating concentrations (10 µg/ml) of eptifibatide or scFv. In a second step, FITC-labeled anti-LIBS-145-mAb (20 µg/ml) was added and incubated for 20 min.
Aggregometry
Blood was collected by venipuncture with a 21 gauge butterfly needle from healthy volunteers and anticoagulated with citric acid. Platelet rich plasma was obtained by centrifugation at 100 g in plastic tubes at room temperature for 15 min in a laboratory centrifuge. Platelet-dependent thrombus formation was detected in light transmission aggregometry using a Biodata PAP-4 aggregometer. After incubation with the scFv or abciximab for 10 min at 37°C, aggregation was induced by addition of ADP (20 µM), collagen (0.19 mg/ml) or thrombin (0.1 µM) with stirring at 900 rpm.
Fingerprinting, sequencing and screening
Phagemid-DNA of randomly picked natural clones was purified and digested with the BstNI restriction enzyme. Then, the scFvs of all individual clones were expressed in the periplasmic product of XL1-blue and small-scale periplasmic preparations were obtained as described (25) . The periplasmic product was then dialyzed against PBS (14.000 MWCO, Spectrapor, Spectrum Laboratories, Rancho Dominguez, California) and tested in flow cytometry with human platelets as described above. In parallel, the level of scFv expression was tested in Western blotting with an HRP-labeled anti-His(6)-antibody (Roche, Basel, Switzerland). Finally, all clones expressing a binding scFv were sequenced using an automated DNA sequencer. Alignment of the amino acid sequences was performed using the Clustal multiple alignment program (HUSAR-package, biocomputing group, German Research Cancer Institute, Heidelberg, Germany)
Binding studies on transiently expressed mutant α IIb β 3
Mouse-human domain switch mutants of both subunits and point mutants of the α IIb subunit were constructed and cloned in the vector pBJ-1 as described (27, 28) . Wild type and mutant cDNA was transfected to CHO cells using the Polyfect transfection reagent (Qiagen, Hilden, Germany) according to the manufacturers recommendations. Cells were harvested after 48h and two color flow cytometry was performed as described with some modifications. Briefly, cells were incubated in succession with PL98DFG6, PE-labeled goat anti mouse-IgG (Dianova), PT25-2 (alternatively with LIBS-2 for scFv MA4), 2 µg/ml scFv and finally with FITC-labeled anti-His(6)-antibody (Dianova).
RESULTS
Primary, specificity-focused selection of conformation-dependent phages
The prerequisite for successful panning is a large library, providing a good chance that antibodies against the desired epitope are actually included. We constructed a natural phage library based on cDNA from peripheral blood lymphocytes and spleen biopsy material and a synthetic library by insertion of randomized synthetic nucleotide-sequences in the complementary-determining region 3 (CDR3) of the variable domain of the heavy chain (V H ). To select phages directed against activation-specific epitopes of the large and complex integrin α IIb β 3 , we used the following combination of panning strategies to reduce non-specific binding and to select for activation-specific scFvs ( Fig. 1): (1) To decrease non-specific binding, we used a washing buffer with a relative low pH (6.5) (29) . (2) We performed panning in series with α IIb β 3 expressed on two different cell types (platelets and α IIb β 3 transfected CHO cells), which are composed of a completely different cell surface background. (3) To deplete all phages binding to the non-activated receptor or the cell background, the phage suspension was primarily incubated with non-activated α IIb β 3 on platelets or CHO cells. (4) Finally, we applied a competitive elution protocol using the α IIb β 3 inhibitor abciximab.
The diversity of the natural clones was identified by the distinct patterns obtained by digestion with the restriction endonuclease BstNI: The clones generated by glycine elution (MA-clones) demonstrated 17 distinct patterns out of 80 randomly picked clones and the clones generated by competitive elution (MB-clones) demonstrated 17 distinct patterns out of 60 total clones ( Fig.  2A) . The binding of the scFvs clones to α IIb β 3 on human platelets and to CHO cells expressing native α IIb β 3 and activated VGFFK-deleted α IIb β 3 was tested in flow cytometry (shown for platelets in Fig. 2B ), and the expression was evaluated in Western blotting. Using this approach, we identified 2 non-activation-specific, 6 activation-specific, and 24 nonbinding clones. Two enriched clones generated with the competitive elution protocol demonstrated very low expression. All other clones were expressed sufficiently to a comparable degree. The best natural clone was enriched by the standard glycine elution, as well as by competitive elution (MA2=MB9). In the case of the synthetic clones, fingerprinting by BstNI-digest was not possible due to the relatively small sequence variability (only in the V H CDR3). Thus, we primarily performed sequencing of twelve clones from the standard elution protocol (SA clones), which revealed a rather small degree of enrichment: Only two sequences were present twice, five clones demonstrated strong binding (see Fig. 2A ). The competitive elution strategy revealed one binding clone (SB4) only from the synthetic library, which was identical to the clone SA2 from the standard elution protocol. Hence, for both libraries competitive elution did not achieve better results than standard elution. This indicates that a sufficient reduction of non-specific phages took place prior to elution. Sequencing of the activation-specific clones revealed that nearly all of them contained an RXD-sequence in their V H CDR3 in analogy to the α IIb β 3 binding RGDsequence in fibrinogen (Fig. 3) . Thus, these findings suggest that the obtained scFvs imitate the natural ligand soluble fibrinogen in its binding properties to the activated α IIb β 3 integrin receptor.
Secondary, affinity-focused selection of phages from a synthetic V L -sublibrary
Since the phages obtained from the synthetic library demonstrated a weak binding and we hypothesized that this might be due to their limited variability (only V H CDR3 was randomized), we performed a secondary panning for optimization of the light-chain CDR3. For this purpose, we constructed a variable light-chain (V L ) sublibrary with randomized V L CDR3's, which resulted in a complexity of 2.6 × 10 8 . We modified the panning procedure with the goal to select phages with high affinity: (1) In contrast to the first specificity-focused panning protocol, a depletion step was omitted. (2) To enhance the competition between phages, a smaller quantity of α IIb β 3 -expressing cells was used. (3) To separate phages with very high affinity, an elution protocol with gradually increasing concentrations of the α IIb β 3 inhibitor eptifibatide was used. Thirty clones, which we named SCE, were then randomly picked and their binding properties were evaluated in flow cytometry (Fig. 4A) . Nearly all clones demonstrated activation-specific binding, and many of them demonstrated binding in flow cytometry comparable with the natural clones. V L sequences of these clones did not demonstrate enrichment of individual clones, and alignment did not reveal common patterns (Fig. 4B) . Of note, the length of the secondary V L CDR3's was significantly shorter (9.7±0.7 amino acids) than the original framework V L CDR3 (13 amino acids).
Inhibitory potency of the selected scFvs
As a next step, we evaluated whether the obtained scFvs could inhibit fibrinogen-binding comparably with the existing α IIb β 3 inhibitors. Therefore, the scFvs MA2, SA2, and SCE5 were cloned in an expression vector (pHOG-21), produced, and purified at a large scale (see Experimental Protocol). Then, the binding of fibrinogen to ADP-stimulated platelets at various scFv concentrations was measured in flow cytometry. As depicted in Fig. 5A , MA2 completely inhibited fibrinogen binding with half-maximal binding at 1.1 µg/ml (36.6 nM). The clinically used GP IIb/IIIa inhibitor abciximab demonstrates a comparable inhibition [half maximal at 0.75 µg/ml (15 nM)]. One of the best synthetic clones (SCE5) also has a comparable inhibitory potency with an IC 50 of 1.2 µg/ml (37 nM). The comparison with the primary clone SA2 clearly demonstrates the improvement of affinity by optimization of the V L CDR3.
To test whether the selected clones could inhibit platelet-dependent thrombus formation, we performed light-transmission aggregometry. First, we tested ADP-induced aggregation as standard test. As depicted in Fig. 5B all three tested clones-MA2, MA4, and SCE5-inhibited platelet aggregation completely at concentrations approximately at 15 µg/ml. In addition, we used alternative platelet agonists: Platelet aggregation induced by thrombin or collagen was also inhibited (Fig. 5C ). As expected with these stronger platelet agonists, the degree of inhibition is less but is still at the same level as the inhibition caused by abciximab.
Exclusion of LIBS-Induction
Because the induction of LIBS epitopes on α IIb β 3 has been associated with thrombocytopenia, we tested whether the binding of the newly designed scFvs cause the expression of LIBS epitopes. For this purpose, we used the anti-LIBS-145-mAb, which demonstrates a considerable shift upon incubation with α IIb β 3 blockers, such as eptifibatide (Fig. 6) . In contrast, incubation with saturating concentrations (10 µg/ml) of the activation-specific single-chain antibodies, as representatively shown for scFv MA2 in Fig. 6 , did not induce binding of the anti-LIBS antibody.
Mapping of the binding sites of the selected clones
Since nearly all of the obtained scFvs contain an RXD pattern, we assumed that they bind at the fibrinogen-binding site on the receptor. This assumption is consistent with the fact that these scFvs are competitive with small RGD peptides and with the monoclonal antibody Pac-1 (data not shown). The only exception to this pattern is the natural clone MA4, which is not inhibited by GRGDSP and does not contain an RXD pattern, but does inhibit fibrinogen binding. Thus, it is likely that inhibition of fibrinogen binding by this antibody might be due to steric hindrance or conformational alterations. To obtain more detailed information about the binding sites of these antibodies, we performed binding studies with mutant α IIb β 3 , which were transiently expressed on the cell surface of CHO cells. To attain the activated conformation of α IIb β 3 , we performed preincubation with the activating mAb PT25-2 (30). First, we tested mouse-human domain switch mutants (27; Fig. 7A ). The underlying principle of this strategy is based on interspecies sequence-variability resulting in anti-α IIb β 3 antibody binding specifically to the human receptor but not to the murine receptor. Indeed, flow cytometry with murine platelets confirmed that this is also the case for all scFv antibodies described in this study (data not shown). Thus, binding studies with human-mouse chimeric receptors that contain distinct murine sequences in the human framework can identify regions that are critical for antibody binding. These distinct nonhomologous regions are defined according to Puzon-McLaughlin et al. (27) by sequence alignment of human and murine cDNA. The individual regions of human α IIb β 3 were "murinized" by the exchange of all non-homologous amino acids within the respective region. The binding of the scFvs on these human-mouse chimeric receptors is depicted in Fig. 7A . In the β 3 -subunit the mutants W129S/N133T [B3, according to Pouzon-McLaughlin et al. (27) ] and D179N/T182N/T183A (B6) demonstrated considerably reduced antibody binding, indicating that these regions are important for antibody binding. However, no single mutation induced complete inhibition of binding of the clones MA2 and SCE5. Thus, we also tested the combination of the mutations B3 and B6, which demonstrates a complete inhibition of binding for all clones. In the α IIb -subunit we detected some differences between the distinct clones, especially for the A16 (V156A/N158S/D159) mutant, for which clone MA2 demonstrates unaltered binding but not clones MA4, SA2, and SCE5.
For a detailed analysis of ligand binding sites on the α IIb -subunit, Kamata et al. (28) have established several alanine exchange point mutations based on a computed model of this region (β propeller model). They have identified several discontinuous individual residues in this region that are critically involved in fibrinogen binding (Fig. 7B ) of α IIb (28) . We performed binding studies with the newly generated scFvs on these point mutants.
As depicted in Fig. 7B , the results of the binding studies with the point mutants of the tested activation-specific scFvs matched with the binding data obtained for fibrinogen by Kamata et al. (28) . Nearly all mutants that demonstrate reduced fibrinogen binding in the original study [as indicated by a (-) below the x-axis] also demonstrated reduced binding of the activation-specific scFv-clones. In conclusion, the mapping studies indicate almost identical binding sites of the newly generated scFvs and fibrinogen.
DISCUSSION
To circumvent limitations of the currently available α IIb β 3 inhibitors, we designed a new type of α IIb β 3 inhibitor, which blocks only the activated conformation of α IIb β 3 . For this purpose, we established a phage display strategy allowing the selection of single-chain antibodies directed against function-dependent epitopes on complex receptors from human naïve phage libraries. By a newly established panning protocol, we selected several activation-specific anti-α IIb β 3 singlechain antibodies that effectively block fibrinogen binding and platelet aggregation.
In contrast to the clones of the natural library, which demonstrate wide variations in binding properties with two outstanding good binders, all clones obtained from the synthetic library demonstrate a weak binding, which might be explained by their limited sequence variability (only V H CDR3 was randomized). Nevertheless, the use of a synthetic library seems to be desirable since it offers various advantages: The library is based on an established framework sequence that allows a high-yield expression of a stable scFv with low immunogenicity. Moreover, this approach is not limited to the natural variability of the human immune system and offers the possibility of affinity improvement by CDR-shuffling (31) . Hence, we carried out a secondary panning with a light-chain sublibrary of the selected primary clones and thereby achieved optimization of the light chain CDR3. The resulting subclones demonstrate an inhibitory potency in the range of the natural clones. Thus, the newly established panning protocol is suitable to select conformation-dependent phages from a naïve "natural" library as well as a synthetic library (see Table 1 ). This panning strategy is transferable to multiple fields of drug discovery, especially for the targeting of integrins and other complex transmembrane receptors. This may be an important step toward the modeling of drugs with specifically tailored binding characteristics.
It is remarkable that most of the activation-specific clones selected here (7 out of 10) contain an RXD-pattern in their heavy-chain CDR3 region, indicating that these antibodies bind to similar epitopes as the natural ligand fibrinogen, which contains RGD sequences. However, sequence alignment did not reveal any additional conserved amino acid patterns that might be responsible for activation specificity. Kunicki et al. (32) found that exchanging the six amino acids Nterminal to the RXD-sequence of the activation-specific mAb Pac-1, against the four amino acids of the non-activation-specific antibody OPG-2, results in loss of activation specificity (32) . Consequently, the authors raised the hypothesis that these amino acids in the loop adjacent to the RXD sequence, and in particular the length of this loop, is responsible for activation specificity. Among the activation-specific clones, which were selected by us, are four that bear exactly six amino acids in the N-terminal part of the V H CDR3-loop, indicating that this might be a favorable length. However, one activation-specific clone with an N-terminal part of the loop with only four amino acids demonstrates that this length does not exclude activation specificity. Most likely, the three-dimensional orientation of the arginine and aspartate, which is influenced but not solely determined by the length of the loop, is a crucial feature for activation specificity. Further sequence analysis based on the single-chain antibodies obtained may allow structural modeling to fully define the detailed structural determinants of activation specificity.
Recently, Chung et al. (33) have presented a phage display protocol enabling the selection of α IIb β 3 -specific single-chain antibodies from a newly designed synthetic library with a randomized CDR3 region containing an RAD pattern. This was a major advance in drug development, since for the first time completely human antibodies that could inhibit platelet aggregation were reported. The authors describe the potential advantages of full human antibodies, especially the avoidance of an immune reaction with anti-mouse antibodies of patients as has been reported for the mouse/human chimeric antibody fragment abciximab. A further goal of Chung et al. (33) was to obtain an α IIb β 3 -specific antibody without crossreactivity with other integrins. Indeed, based on our panning protocol we also selected α IIb β 3 -specific single-chain antibodies. This was proven by using CHO cell lines expressing wild-type and mutated, activated α v β 3 , as well as α M β 2 (Mac-1) (data not shown). For both integrins, crossreactivity was reported for abciximab (14, 34) . The major difference to the phage display used by Chung et al. (33) was our goal to obtain unique activation-specific single-chain antibodies promising to provide the below-discussed additional advantages. Since the conformational state of the receptor was not an issue, immobilized target protein could be used for panning by Chung et al. (33) , whereas in our approach, we had to establish a new subtractive panning procedure. Moreover, in the present study we used naïve libraries without a predefined RXD pattern in the CDR3 region. This protocol can be broadly used without the knowledge of a predefined binding sequence. It is remarkable, however, that all activation-specific clones selected by us, with only one exception (MA4), contained an RXD pattern, arguing for a highly effective panning procedure.
To gain more comprehensive information about the interaction of these activation-specific scFvs, we performed binding studies with four representative clones on mouse-human switch receptor mutants and α IIb point mutants (27, 28) . The results obtained with these mutants indicate discontinuous binding sites on both subunits, which are overall comparable with that of fibrinogen and of the ligand mimetic antibody Pac-1. In the initial description of these mutants, the main difference between the natural ligand fibrinogen and ligand-mimetic antibodies, like Pac-1, was found to be in the domain A16 (156-162), which is located in a predicted loop at the boundary between repeats two and three of the α subunit. This mutant demonstrates increased binding of fibrinogen and complete inhibition of Pac-1 binding. Intriguingly, the natural scFv MA2, like fibrinogen, binds to mutant A16 with high affinity, whereas the other clones demonstrate reduced binding. Thus, the binding site of clone MA2 is more similar to that of the existing ligand-mimetic antibodies, whereas the binding site of the other clones appears to be identical with the fibrinogen-binding site. As a final point, it is noteworthy that the synthetic subclone SCE5, which has an optimized light chain, does not demonstrate any additional binding sites compared with its precursor SA2. This observation is consistent with the fact that no specific amino acid patterns were enriched in the light-chain CDR3 sequences of the secondary clones, and this observation might indicate that the light-chain optimization is important for the reduction of disturbing structures rather then to promote additional interactions with the epitope.
The human single-chain antibodies obtained in this study are a promising basis for a new type of α IIb β 3 -blocking agents with several potential advantages: (1) Activation-specific inhibitors promise not to inhibit α IIb β 3 -mediated platelet adhesion to immobilized fibrinogen, which is for example exposed on injured vessel walls. Thereby, the formation of a platelet monolayer at the site of vascular injury may still be possible. In vivo experiments will have to determine whether this theoretical advantage will be translated in a clinical advantage with fewer bleeding complications. (2.) Activation-specific scFv do not bind and do not induce LIBS expression on resting platelets. Because thrombocytopenia is attributed mainly to an immune response directed against LIBS epitopes (35, 36) , α IIb β 3 inhibitor-induced thrombocytopenia may therefore be avoided. Furthermore, the higher frequency of thrombocytopenia seen with the use of abciximab, compared with the lower frequency seen with the non-antibody-based α IIb β 3 inhibitors, is generally explained by patient antibodies directed against the murine sequences still present in abciximab, which is a mouse/human chimeric antibody fragment (37) . Since our single-chain antibodies are fully of human origin, this potential source of thrombocytopenic reaction is avoided. (3.) ScFv antibodies, which have already been successfully clinically used (38, 39) , demonstrate several advantages compared with mouse-derived antibodies or their fragments (e.g., Fab): The smaller size might result in favorable pharmacological properties, such as faster elimination and better penetration of thrombi. The complete human origin of the scFv promises negligible immunogenicity (17) . And finally, the production in bacteria offers the facility of genetic engineering, such as further optimization and the construction of fusion molecules (40) .
In conclusion, we established a differential subtractive phage display protocol suitable to obtain conformation-dependent single-chain antibodies against the platelet integrin receptor α IIb β 3 from naïve synthetic and natural phage libraries. We provide evidence that these antibodies demonstrate an inhibitory potency comparable with the presently used α IIb β 3 inhibitors and that they bind at or near to the discontinuous fibrinogen binding site on both subunits. The antibodyfragments obtained here represent useful tools for the investigation of integrin-ligand interactions; they represent markers for the activation of α IIb β 3 and platelets in general and promise to be the basis for the development of a new type of activation-specific α IIb β 3 inhibitor. Figure 1 . Scheme of the differential panning strategy. This strategy was developed to reduce non-specific (depicted in gray) and non-activation-specific binding phages (depicted in blue) and to specifically select phages binding to epitopes on α IIb β 3 expressed solely on the activated receptor (depicted in red). The first round (upper row) was performed on human platelets. Initially, a depletion step was performed where all phages that bound to non-activated α IIb β 3 or the platelet background were separated by centrifugation and discarded. The supernatant was used for the next selection step in which the non-binding phages in the supernatant were discarded and the binding phages were rescued and eluted by lowering the pH or by competition with the α IIb β 3 inhibitor abciximab. The obtained phages were then amplified in E. coli and used for the next round. In the following two rounds the cell background was changed by using recombinant α IIb β 3 -expressing CHO cells to avoid enrichment of phages binding to activation-specific platelet epitopes other than on the α IIb β 3 molecule. 6 . LIBS-145-expression. The ligand induced conformational change was monitored using FITC-labeled anti-LIBS-145-mAb. The histograms depict anti-LIBS-145-mAb (20 µg/ml) binding to platelets (black histograms) after incubation with eptifibatide (10 µg/ml, upper histograms) and scFv MA2 (10 µg/ml, lower histograms) compared with the control without eptifibatide or scFv MA2 (grey histograms), respectively. Fig. 7 (cont)   Figure 7 . A) Binding of scFv clones to α IIb β 3 mouse-human mutants. Human-to-mouse mutations alone or in groups were transiently expressed in CHO cells, and binding of four representative scFv clones was evaluated in flow cytometry. The non-function-specific anti-α IIb mAb PL98DF6 was used for detection of the expression level and gating of α IIb β 3 -expressing cells, and activating PT 25-2 (or for clone MA4 mAb LIBS-2) was used for induction of the active conformation. Depicted is the binding index of the various scFvs as the mean fluorescence measured in flow cytometry on the mutant receptor compared with the wild-type receptor. Positions of mutations in the human to mouse α IIb mutants are A9: V79L/S81F/T83I/L84F; A16: V156A/N158S/D159 deltion/S161R/W162G; A23: E229V/Y230F; A24, W235R. Positions of mutations in the human to mouse β 3 mutants are B3: W129S/N133T; B4: T140S; B5: E171Q/L173I/E174K; B6: D179N/T182N/T183A; B7: T201S; B8: Q267L. For direct comparison, the binding of fibrinogen and Pac-1 to mutant receptors, as published by Puzon-McLaughlin et al. (27) , are given in the table below the graph. The strength of binding is represented as follows: (-) 0-5%; (+) 5-20%, (++) 20-60%, (+++) 60-90%, (++++) >90%. For better comparison this scale is also given on the y-axis. B) Binding of scFv clones to β-propeller point mutants. α IIb Point mutations in the predicted loops of the β-propeller model, which have been shown to be critically involved in ligand binding, were evaluated regarding to their ability to bind the distinct scFv clones. For direct comparison, the binding of fibrinogen to mutant receptors, as published by Kamata et al. (28) , are given in the table below the graph. The strength of binding is represented as follows: (-) 0-5%, (+) 5-20%, (++) 20-60%, (+++) 60-90%, (++++) >90%. For better comparison, this scale is also given on the y-axis.
